AI Article Synopsis
- The study investigates the effectiveness of the oral antiviral nirmatrelvir-ritonavir in preventing post-COVID-19 conditions (PCCs) among nonhospitalized veterans who tested positive for COVID-19.
- Conducted through a retrospective analysis, it compares outcomes of veterans treated with the antiviral to those who did not receive treatment over a period spanning 31 to 180 days post-infection.
- Results showed no significant differences in the incidence of most PCCs between treated and untreated groups, but a notable reduction in venous thromboembolism and pulmonary embolism was observed in those treated with nirmatrelvir-ritonavir.
Article Abstract
Background: COVID-19 has been linked to the development of many post-COVID-19 conditions (PCCs) after acute infection. Limited information is available on the effectiveness of oral antivirals used to treat acute COVID-19 in preventing the development of PCCs.
Objective: To measure the effectiveness of outpatient treatment of COVID-19 with nirmatrelvir-ritonavir in preventing PCCs.
Design: Retrospective target trial emulation study comparing matched cohorts receiving nirmatrelvir-ritonavir versus no treatment.
Setting: Veterans Health Administration (VHA).
Participants: Nonhospitalized veterans in VHA care who were at risk for severe COVID-19 and tested positive for SARS-CoV-2 during January through July 2022.
Intervention: Nirmatrelvir-ritonavir treatment for acute COVID-19.
Measurements: Cumulative incidence of 31 potential PCCs at 31 to 180 days after treatment or a matched index date, including cardiac, pulmonary, renal, thromboembolic, gastrointestinal, neurologic, mental health, musculoskeletal, endocrine, and general conditions and symptoms.
Results: Eighty-six percent of the participants were male, with a median age of 66 years, and 17.5% were unvaccinated. Baseline characteristics were well balanced between participants treated with nirmatrelvir-ritonavir and matched untreated comparators. No differences were observed between participants treated with nirmatrelvir-ritonavir ( = 9593) and their matched untreated comparators in the incidence of most PCCs examined individually or grouped by organ system, except for lower combined risk for venous thromboembolism and pulmonary embolism (subhazard ratio, 0.65 [95% CI, 0.44 to 0.97]; cumulative incidence difference, -0.29 percentage points [CI, -0.52 to -0.05 percentage points]).
Limitations: Ascertainment of PCCs using International Classification of Diseases, 10th Revision, codes may be inaccurate. Evaluation of many outcomes could have resulted in spurious associations with combined thromboembolic events by chance.
Conclusion: Out of 31 potential PCCs, only combined thromboembolic events seemed to be reduced by nirmatrelvir-ritonavir.
Primary Funding Source: U.S. Department of Veterans Affairs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620954 | PMC |
| http://dx.doi.org/10.7326/M23-1394 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analytical review of facial nerve palsy following SARS-CoV-2 vaccination: comprehensive assessment.
Eur Arch Otorhinolaryngol
January 2025
Department of Otolaryngology-Head and Neck Surgery, Temerty Faculty of Medicine, University of Toronto, 6 Queen's Park Crescent West, Suite 120, Toronto, ON, M5S 3H2, Canada.
Purpose: The SARS-CoV-2 vaccination has reduced COVID-19 infection, though facial nerve palsy (FNP) has emerged as a notable side effect of the vaccine. We evaluated the current literature on the clinical presentation and outcomes of FNP related to COVID-19 vaccination.
Methods: A comprehensive search of seven databases was conducted for studies up to January 2023.
Acoustic Characteristics of Voice and Speech in Post-COVID-19.
Healthcare (Basel)
January 2025
Department of Computer Science, Institute of Mathematics and Statistics, University of São Paulo (USP), São Paulo 05508-220, SP, Brazil.
Background/objectives: The aim of this paper was to compare voice and speech characteristics between post-COVID-19 and control subjects. The hypothesis was that acoustic parameters of voice and speech may differentiate subjects infected by COVID-19 from control subjects. Additionally, we expected to observe the persistence of symptoms in women.
View Article and Find Full Text PDFPerceived Telehealth Usability for Personalized Healthcare Among the Adult Population in Saudi Arabia: A Cross-Sectional Study in the Post-COVID-19 Era.
Healthcare (Basel)
January 2025
Public Health Department, College of Health Sciences, Saudi Electronic University, Riyadh 11673, Saudi Arabia.
: Due to technological advancements, the demand for easily accessible and convenient healthcare services is rising globally. Thus, telehealth is gaining momentum that was previously unheard of. The Kingdom of Saudi Arabia (KSA) actively embraces digital innovation in the healthcare industry through its ambitious Vision 2030 initiative.
View Article and Find Full Text PDFThe association between underlying conditions, risk factors, risk markers, and post-COVID conditions ≥6 months after COVID-19: A systematic review.
J Family Med Prim Care
December 2024
National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, USA.
Introduction: While various demographic factors and underlying medical conditions are associated with the development of post-COVID conditions within a month after SARS-CoV-2 infection, less is known about factors associated with post-COVID symptoms that persist for 6 months or more. The aim of this review was to determine the association between underlying conditions, other risk factors, health behaviors, and the presence of symptoms ≥6 months after COVID-19.
Methods: Studies reporting on post-COVID symptoms were searched in databases, including Medline, EMBASE, Global Health, PsycInfo, Scopus, CINAHL, Proquest, and WHO COVID-19 literature, from the beginning of the pandemic until November 2022.
Evaluation of the long-term effects of COVID-19 on pulmonary functions in recovered patients.
J Family Med Prim Care
December 2024
Vice Chancellor, Atal Bihari Vajpayee Medical University, Lucknow, Uttar Pradesh, India.
Background: It is documented that COVID-19 survivors have prolonged morbidity and functional impairment for many years. Data regarding post-COVID-19 lung functions is lacking from the Indian population. We aim to evaluate the lung functions in such patients after 3-6 months of hospital discharge.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!